Shopping Cart
- Remove All
- Your shopping cart is currently empty
HSP90-IN-31 (compound Be01) reduces the expression of CD80 and CD86 on dendritic cells (DC). It also diminishes the production of pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β) in bone marrow-derived dendritic cells (BMDC) and peritoneal macrophages stimulated by LPS. Additionally, in a delayed-type hypersensitivity (DTH) mouse model, HSP90-IN-31 alleviates ear swelling and decreases pro-inflammatory cytokines in the spleen.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | HSP90-IN-31 (compound Be01) reduces the expression of CD80 and CD86 on dendritic cells (DC). It also diminishes the production of pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β) in bone marrow-derived dendritic cells (BMDC) and peritoneal macrophages stimulated by LPS. Additionally, in a delayed-type hypersensitivity (DTH) mouse model, HSP90-IN-31 alleviates ear swelling and decreases pro-inflammatory cytokines in the spleen. |
Molecular Weight | 384.47 |
Formula | C22H28N2O4 |
Cas No. | 2117645-10-8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.